Comparison of the efficacy and safety of iguratimod and hydroxychloroquine in the treatment of Sjogren's syndrome
XU Dong
LV Xiaowei
CUI Peng
MA Shangmin
Abstract：Objective To compare the efficacy and safety of iguratimod and hydroxychloroquine in the treatment of Sjogren's syndrome.Methods Ninety-four cases of patients with Sjogren's syndrome were selected, who were treated in department of rheumatology of the First Hospital of Zibo City from January 2016 to January 2017, they were divided into the observation group (47 cases) and control group (47 cases).The patients of control group were treated with methylprednisolone tablets (8 mg / time, morning meal, 1 time / d) and hydroxychloroquinoline sulfate (0.2 g / time, 2 times / d).The patients of observation group were treated with methylprednisolone (8 mg / time, morning meal, 1 time / d) and alamomide tablets (oral, 25 mg / time, 2 times / d).The patients of 2 groups were all treated for 3 months.Compare the clinical effect, adverse reactions and changes of the ESR, IgG, RF, PLT, ESSDAI score, ESSPRI score, Schirmeri test and saliva flow rate of two groups.Results After treatment, the patients of the observation group got a total effective rate of 93.6%, which was significantly better than the 76.6% of the control group (χ2=5.371, P =0.020);The ESR, IgG, RF, ESSDAI, ESSPRI scores of the observation group were significantly lower than those of the control group, and the PLT counts, Schirmeri test, saliva flow rate of the observation group were significantly higher than those of the control group (t =3.115、6.921、3.239、5.346、10.011、4.368、6.263、5.819;P <0.01);There were gastrointestinal discomfort, abnormal liver function, rash, itching, leukopenia and other adverse reactions occurred in both two groups, but there were no statistically significant between the two groups (χ2=0.255、2.272、0.435、0.781、2.122, P >0.05).Conclusion Compared with hydroxychloroquine, iguratimod for treating Sjogren's syndrome can achieve more precise results, effectively reduce the activity of serum B lymphocyte, and it is safe and reliable, which makes it worthy of clinical application.
Keywords：IguratimodHydroxychloroquineSjogren's syndromeEffectSafety
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 915-918 )